Pegozafermin
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Pegozafermin
- bio89 100
- bio89 100 long acting glycopegylated fibroblast growth factor 21 fgf21 analogue
- Bio89-100
- BIO89-100
- BIO89-100 (LONG-ACTING GLYCOPEGYLATED FIBROBLAST GROWTH FACTOR 21 (FGF21) ANALOGUE)
- bio89100
- BIO89100
- FIBROBLAST GROWTH FACTOR 21 (METHIONYL,173-(O-(2-(ACETYLAMINO)-6-O-(N-(2-(CARBOXYAMINO)ACETYL)-.ALPHA.-NEURAMINOSYL)-2-DEOXY-.ALPHA.-D-GALACTOPYRANOSYL)THREONINE),176-ARGININE) (HUMAN CONSTRUCT BIO89-100), 173N-ESTER WITH .ALPHA.-HYDRO-.OMEGA.-METHOXYPOLY(OXY-1,2-ETHANEDIYL)
- fibroblast growth factor 21 methionyl 173 o 2 acetylamino 6 o n 2 carboxyamino acetyl alpha neuraminosyl 2 deoxy alpha d galactopyranosyl threonine 176 arginine human construct bio89 100 173n ester with alpha hydro omega methoxypoly oxy 1 2 ethanediyl
- pegozafermin
- Pegozafermin
- pegozafermin [INN]
- PEGOZAFERMIN [USAN]
- pegozafermin inn
- pegozafermin usan
- pegozafermina
- Pegozafermina
- pegozafermine
- Pegozafermine
- tev 47948
- TEV-47948
- CAS registry numbers
- 2489589-60-6
- ChEMBL ID
- CHEMBL4594466
- FDA ingredient codes (UNII)
- UO870O6MFS
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- pegozafermin
- Type
- Peptide
- Drug name stem
- -ermin; peg-
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- fibroblast growth factor receptor 1
- Gene symbol
- FGFR1
- Protein identifier
- P11362
- Median affinity
- 9.22
- Affinity units
- pEC50
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition
- Hypertriglyceridemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004211
- Subject identifier
- D015228
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001249
- Subject identifier
- D065626
- Condition identifier
- EFO_0003095
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004211
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006890
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001249
- Highest recorded phase
- 3
- Condition identifier
- HP_0001395
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005347
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013209
- Highest recorded phase
- 1
- NCT04048135
- NCT04929483
- NCT05022693
- NCT04541186
- NCT05852431
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- MHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPTQGASPSYAS
- Component
- Disulfide bridges
- Sequence
- 76-94
Related records
Trials (7)
- A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
- Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
- Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
- To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia